What the Company Does

Precision Neuroscience develops technology that sits on the surface of the brain to record neural activity. Rather than penetrating brain tissue with electrodes, the company's approach uses an ultra-thin film that conforms to the surface of the cerebral cortex. This surface-based (rather than penetrating) design is intended to reduce the risk of damage to brain tissue and to allow the device to be implanted and removed with minimal disruption.

The signals collected by the interface are processed and translated into digital commands. The long-term goal is to enable individuals who have lost the ability to move or speak—due to conditions such as spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), or other neurodegenerative disorders—to control digital devices, communicate, and interact with the world using their neural activity.

The company has pursued a strategy of gathering clinical data through work with patients undergoing neurosurgical procedures, allowing its technology to be tested and refined in real-world medical settings. This clinical engagement is a key part of how Precision develops and validates its systems.

Core Technology and Products

Layer 7 Cortical Interface

The flagship product of Precision Neuroscience is the Layer 7 Cortical Interface. The name references the layered structure of the cerebral cortex. The Layer 7 is an extremely thin, flexible microelectrode array designed to rest on the surface of the brain without penetrating the tissue.

Key characteristics of the Layer 7 Cortical Interface include:

• Thinness: The array is significantly thinner than a human hair, allowing it to conform closely to the folds and contours of the brain's surface.

• High electrode density: The device packs a large number of electrodes into a compact area, enabling high-resolution recording of neural signals across the cortical surface.

• Minimally invasive implantation: The design allows the array to be inserted through a very small cranial opening, reducing the invasiveness of the procedure compared to approaches that require larger openings or tissue penetration.

• Reversibility: Because the device sits on the surface rather than embedding within brain tissue, it is intended to be removable, which is an important consideration for patient safety and future upgrades.

Regulatory Progress

Precision Neuroscience has advanced its technology through the U.S. regulatory process. The company received clearance from the U.S. Food and Drug Administration (FDA) for a component of its wired electrode array system. This clearance relates to the use of the electrode array to record, monitor, and stimulate electrical activity on the surface of the brain for limited durations, which supports clinical and research applications. Achieving FDA clearance is a significant milestone for a company in the brain-computer interface field and reflects progress toward broader medical use.

Services and Applications

The primary applications that Precision Neuroscience is working toward include:

• Restoring communication for individuals who have lost the ability to speak.

• Enabling control of computers, digital devices, and assistive technologies through neural signals for people with paralysis.

• Providing high-resolution brain mapping data that can assist neurosurgeons during procedures and support research into brain function.

• Advancing the understanding of neurological conditions through the detailed data collected by its high-density electrode arrays.

The company's technology has potential relevance across a range of conditions, including spinal cord injuries, stroke, ALS, and other disorders that affect motor control and communication.

Approach and Differentiation

Precision Neuroscience distinguishes itself within the competitive brain-computer interface landscape through its emphasis on a minimally invasive, surface-based design. While some companies in the field pursue electrodes that penetrate into brain tissue to capture signals from deeper structures, Precision has chosen to focus on a conformable film that stays on the cortical surface. This choice reflects the company's priorities around safety, reversibility, and the ability to scale the technology to serve large numbers of patients.

The founding team's background, particularly the involvement of professionals with prior experience in the BCI industry and in neurosurgery, has shaped the company's technical direction and clinical strategy.

Company Background and Funding

Since its founding, Precision Neuroscience has attracted investment to support the development and clinical testing of its technology. The company is headquartered in the United States, with operations that include research, engineering, and manufacturing efforts to bring its neural interface systems toward commercial and clinical readiness. The company has raised multiple rounds of funding from venture capital and other investors interested in the emerging neurotechnology sector.

Significance

Precision Neuroscience operates at the frontier of medical technology, in a field that combines neuroscience, engineering, microfabrication, and clinical medicine. Brain-computer interfaces represent a rapidly developing area with the potential to transform the lives of people living with severe neurological impairments. By focusing on a safe, thin, and removable interface, Precision aims to make this technology accessible and practical for real patients, while contributing to the broader scientific understanding of how the brain works.

The company's progress through FDA clearance and clinical engagement positions it as a notable participant in the growing neurotechnology industry, where the challenges of safety, signal quality, and scalability are central to bringing brain-computer interfaces from experimental settings into widespread medical use.